» Articles » PMID: 33791278

Recent Advances in the Synthesis of High Boron-Loaded Nucleic Acids for BNCT

Overview
Journal Front Chem
Specialty Chemistry
Date 2021 Apr 1
PMID 33791278
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Boron clusters attract considerable attention as promising therapeutic tools for boron neutron capture therapy (BNCT). They combine high boron content with high chemical and biological stability, biorthogonality, and low toxicity. The development of oligonucleotide-based constructs and nucleic acid-like molecules, such as oligomeric phosphate diesters, bearing one or multiple boron clusters permits to create potential high boron-loaded agents for BNCT with good bioavailability, specifically interacting with nucleic acids inside the cell. Here, we shortly review the strategies and solutions in the design of oligonucleotide conjugates with boron clusters in light of the requirements for effective BNCT and future prospects of their practical use.

Citing Articles

Ultrasound Combination to Improve the Efficacy of Current Boron Neutron Capture Therapy for Head and Neck Cancer.

Yura Y, Fujita Y, Hamada M Cancers (Basel). 2024; 16(15).

PMID: 39123497 PMC: 11311392. DOI: 10.3390/cancers16152770.


Targeting the organelle for radiosensitization in cancer radiotherapy.

Sun X, Wu L, Du L, Xu W, Han M Asian J Pharm Sci. 2024; 19(2):100903.

PMID: 38590796 PMC: 10999375. DOI: 10.1016/j.ajps.2024.100903.


The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning.

Mushtaq S, Ae P, Kim J, Lee K, Kim K Theranostics. 2023; 13(15):5247-5265.

PMID: 37908724 PMC: 10614688. DOI: 10.7150/thno.88998.


Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies.

Monti Hughes A, Hu N Cancers (Basel). 2023; 15(16).

PMID: 37627119 PMC: 10452654. DOI: 10.3390/cancers15164091.


Sweet Battle of the Epimers─Continued Exploration of Monosaccharide-Derived Delivery Agents for Boron Neutron Capture Therapy.

Matovic J, Bahrami K, Stockmann P, Sokka I, Khng Y, Sarparanta M Mol Pharm. 2023; 20(6):3127-3139.

PMID: 37134022 PMC: 10245378. DOI: 10.1021/acs.molpharmaceut.3c00119.


References
1.
Wickstrom E . DNA and RNA derivatives to optimize distribution and delivery. Adv Drug Deliv Rev. 2015; 87:25-34. PMC: 4504810. DOI: 10.1016/j.addr.2015.04.012. View

2.
Janczak S, Olejniczak A, Balabanska S, Chmielewski M, Lupu M, Vinas C . Boron Clusters as a Platform for New Materials: Synthesis of Functionalized o-Carborane (C2 B10 H12 ) Derivatives Incorporating DNA Fragments. Chemistry. 2015; 21(43):15118-22. DOI: 10.1002/chem.201502822. View

3.
Meschaninova M, Novopashina D, Semikolenova O, Silnikov V, Venyaminova A . Novel Convenient Approach to the Solid-Phase Synthesis of Oligonucleotide Conjugates. Molecules. 2019; 24(23). PMC: 6930482. DOI: 10.3390/molecules24234266. View

4.
Guan L, Wims L, Kane R, Smuckler M, Morrison S, Hawthorne M . Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization. Proc Natl Acad Sci U S A. 1998; 95(22):13206-10. PMC: 23761. DOI: 10.1073/pnas.95.22.13206. View

5.
Barth R, Mi P, Yang W . Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018; 38(1):35. PMC: 6006782. DOI: 10.1186/s40880-018-0299-7. View